CT/NG Testing Services - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The cT/NG testing services market size is projected to expand from USD 2.54 billion in 2025 and USD 2.73 billion in 2026 to USD 3.93 billion by 2031, registering a CAGR of 7.53% between 2026 to 2031. This report is Segmented by Test Type (CT Services, NG Testing Services, and More), Technology (NAAT Services, and More), Sample Type (Urine Samples, Vaginal and Cervical Swabs, and More), Testing Mode (Centralized Laboratory Testing, and More), End User (Reference Laboratories, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD),

Global CT/NG Testing Services Market Trends and Insights

Rising Asymptomatic Infection Burden Expands the Screened Population

A large share of CT and NG infections remains silent, which keeps the clinical burden higher than routine case reporting suggests. The CT/NG testing services market benefits from this gap because public health systems need screening programs to identify infections before complications appear. A 2025 study in Frontiers in Public Health estimated global chlamydial incidence at 235.7 million cases in 2021, with an age-standardized incidence rate of 2,902 per 100,000 population. A 2025 study in BMC Infectious Diseases from Hangzhou found no significant change in CT or NG prevalence between 2018 and 2024 at the study site, which shows how persistent the reservoir remains even after years of control efforts. This sustained reservoir supports recurring outreach, repeat testing, and broader screening pathways, which keep the CT/NG testing services market tied to hidden prevalence rather than only to reported case counts.

Broader Screening for Sexually Active Under-25 Populations Institutionalizes Demand

The CT/NG testing services market gains stability when screening moves from physician discretion to formal quality and coverage frameworks. In the United States, the NCQA chlamydia screening measure keeps health plans focused on testing performance for eligible populations, which supports recurring demand at the payer level. CMS preventive services coverage also supports routine sexually transmitted infection screening for eligible beneficiaries, which reduces direct payment barriers in covered settings. Once screening becomes part of plan performance and covered preventive care, volumes are less sensitive to short-term swings in reported prevalence. This creates a predictable floor for the CT/NG testing services market and supports lab investment in capacity, automation, and provider network expansion.

Social Stigma and Privacy Concerns Constrain Test-Seeking Behavior

Social stigma still keeps a meaningful share of infected people away from testing, even where diagnostic tools are available. The CT/NG testing services market, therefore, faces a demand ceiling that cannot be solved by equipment expansion alone. A 2026 multicenter study in southern China found that more than 75% of patients with gonorrhea at Shenzhen clinics were not tested during their most recent visit, and only 37.7% had confirmed positive results, which shows how behavior and care processes still leave major detection gaps. Home testing addresses part of the privacy problem, but the current over-the-counter option cited in the input is limited to female users, which narrows the full reach of private testing pathways. Until routine wellness visits, opt-out screening, and broader private testing formats become more common, stigma will continue to slow the CT/NG testing services market in several high-burden populations.

Other drivers and restraints analyzed in the detailed report include:

• Multiplex CT/NG Panels Reducing Repeat Sample Collection Increase Revenue per Encounter
• Home Collection and Telehealth-Fulfilled Testing Adoption Opens Non-Clinical Demand
• Cost Pressure on Multiplex Molecular Assays Slows Market Penetration in Price-Sensitive Settings

Segment Analysis

Combined CT/NG testing services held 58.24% share in 2025, which made it the largest test-type segment in the CT/NG testing services market. This position reflects the clinical preference for co-testing when either infection is suspected and the operational ease of using one encounter to rule in or rule out both pathogens. The segment also benefits from the fact that co-infection is clinically meaningful, so combined ordering is often seen as standard care rather than as an optional add-on. Billing support has also improved the case for combined panels in the United States. EmblemHealth added CPT code 0455U to chlamydia and gonorrhea screening coverage effective July 1, 2024, which supports clearer reimbursement pathways for panel-based ordering.

Chlamydia testing services are projected to grow at an 8.12% CAGR from 2026 to 2031, making it the fastest-growing test-type segment in the CT/NG testing services market. Growth is linked to wider screening in primary care, family planning clinics, and urgent care settings where CT screening is more routinely emphasized, especially for younger women. The CDC’s enhanced Gonococcal Isolate Surveillance Project keeps gonorrhea testing strategically important, but CT screening reaches a broader preventive care base and supports more repeat testing cycles CDC.GOV. Updated guidelines in China and India published in 2024 also support the spread of evidence-based CT testing into routine STI workflows, which broadens the standalone opportunity outside mature Western markets. As these protocols move into more clinics, standalone CT testing captures incremental demand that combined testing does not yet fully absorb across all settings in the CT/NG testing services market.

NAAT services held 73.67% share in 2025, which confirmed their structural lead across the CT/NG testing services market. This dominance rests on higher sensitivity, faster reporting, and broad clinical acceptance across centralized and decentralized settings. The performance data for newer molecular platforms continues to support this position. A 2025 Journal of Clinical Microbiology study found strong sensitivity and specificity for a rapid multiplex CT/NG/MG assay across specimen types, which reinforces confidence in advanced molecular testing models. NAAT also aligns well with self-collection, automated high-throughput labs, and multiplex menu expansion, which keeps it at the center of both public health and commercial testing workflows in the CT/NG testing services market.

Culture-based testing services are projected to grow at an 8.94% CAGR through 2031, even though it remains smaller than molecular testing in the CT/NG testing services market. This growth is tied less to first-line diagnosis and more to gonorrhea resistance surveillance, where viable organisms are still needed for susceptibility work. Australia’s Public Health Laboratory Network updated its national NAAT guidelines in 2025 and supported supplemental culture use for certain non-urogenital gonorrhea specimens to strengthen antimicrobial surveillance. A 2025 Eurosurveillance study screened 54,837 gonococcal genomes and identified 17 diagnostic-escape variants linked to the Xpert CT/NG assay across 5 countries, which showed that NAAT-only systems can develop blind spots. That risk does not reduce NAAT’s lead, but it creates a durable secondary role for culture in reference settings across the CT/NG testing services market.

Complete Report Scope:

• By Test Type
  • Chlamydia (CT) Testing Services
  • Gonorrhea (NG) Testing Services
  • Combined CT/NG Testing Services
• By Technology
  • Nucleic Acid Amplification Testing (NAAT) Services
  • Culture-Based Testing Services
  • Immunoassay-Based Testing Services
  • Others
• By Sample Type
  • Urine Samples
  • Vaginal and Cervical Swabs
  • Urethral Swabs
  • Rectal and Pharyngeal Swabs
  • Others
• By Testing Mode
  • Centralized Laboratory Testing
  • Point-of-Care Testing Services
  • At-Home Collection and Laboratory Testing Services
• By End User
  • Reference Laboratories
  • Hospital and Clinical Laboratories
  • Public Health Laboratories
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 39.55% of global revenue in 2025, which gave the region the largest share in the CT/NG testing services market. The region benefits from formal screening measures, broad private insurance participation, and preventive coverage frameworks that support repeat testing cycles. NCQA’s chlamydia screening measure keeps payer attention on testing performance, while CMS preventive services coverage helps support access for eligible beneficiaries. North America also has a stronger commercial base for self-collection and consumer-led testing than most other regions. Quest Diagnostics completed its Corewell Health laboratory joint venture in Michigan in January 2026, which shows that major operators are still investing in added processing infrastructure as the CT/NG testing services market expands.

Europe remained the second-largest regional revenue base in the CT/NG testing services market. The region includes several large diagnostic networks and operates across diverse reimbursement systems, which creates uneven testing intensity across countries. At the same time, the IVDR framework raises compliance demands and tends to favor larger organizations with stronger regulatory resources. Altona Diagnostics launched its FlexStar STI panel under full IVDR compliance in 2025, which reflects how larger and better-prepared suppliers are adapting to the new environment. The United Kingdom remains notable because its population screening framework gives Europe one of its more organized testing pathways outside the United States.

Asia-Pacific is projected to grow at a 12.38% CAGR from 2026 to 2031, making it the fastest-growing regional block in the CT/NG testing services market. The region combines structural underdiagnosis with updated national guidelines, which creates a large runway for expansion. A 2025 Hangzhou study reported no significant reduction in CT or NG prevalence between 2018 and 2024, which points to ongoing diagnostic gaps in care pathways. China updated its CT urogenital infection guideline in 2024, and India issued new national technical guidance on STIs in 2024, both of which support wider evidence-based molecular testing. Middle East and Africa presents longer-term potential as private healthcare investment rises in selected markets, and the WHO’s STI prevalence database launched in July 2026 adds a stronger epidemiological basis for future testing expansion. South America still faces reimbursement fragmentation and public lab funding pressure, but urban laboratory networks are beginning to adopt broader molecular workflows in the CT/NG testing services market.

List of Companies Covered in this Report:

• Aclara Technologies (ACL Laboratories)
• ARUP Laboratories
• binx health
• BioReference Laboratories
• Cerba Healthcare
• Clinical Reference Laboratory
• Eurofins
• Healius Limited
• LabCorp
• LetsGetChecked
• Mayo Clinic Laboratories
• PathCare.AI
• Quest Diagnostics
• Sonic Healthcare
• SYNLAB AG
• Unilabs

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support